Evidence map›Paper›PMID 35547661›Full record

ArticleFrontiers in medicine2021

Technical Design Report for a Carbon-11 Treatment Facility.

Liviu Penescu, Thierry Stora, Simon Stegemann, Johanna Pitters, Elisa Fiorina, Ricardo Dos Santos Augusto, Claus Schmitzer, Fredrik Wenander, Katia Parodi, Alfredo Ferrari and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 6 countries.

Liviu PenescuAbstract Landscapes, Montpellier, France.
Thierry StoraEuropean Organization for Nuclear Research (CERN), Geneva, Switzerland.
Simon StegemannDepartment of Physics and Astronomy, KU Leuven, Geel, Belgium.
Johanna PittersEuropean Organization for Nuclear Research (CERN), Geneva, Switzerland.
Elisa FiorinaIstituto Nazionale di Fisica Nucleare (INFN), Sezione di Torino, Torino, Italy.
Ricardo Dos Santos AugustoEuropean Organization for Nuclear Research (CERN), Geneva, Switzerland.
Claus SchmitzerMedAustron, Wiener Neustadt, Austria.
Fredrik WenanderEuropean Organization for Nuclear Research (CERN), Geneva, Switzerland.
Katia ParodiLudwig Maximilian University of Munich (LMU), Munich, Germany.
Alfredo FerrariEuropean Organization for Nuclear Research (CERN), Geneva, Switzerland.
Thomas E CocoliosDepartment of Physics and Astronomy, KU Leuven, Geel, Belgium.
European Organization for Nuclear Research · CHKU Leuven · BEIstituto Nazionale di Fisica Nucleare, Sezione di Torino · ITLudwig-Maximilians-Universität München · DEMedAustron · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Particle therapy relies on the advantageous dose deposition which permits to highly conform the dose to the target and better spare the surrounding healthy tissues and organs at risk with respect to conventional radiotherapy. In the case of treatments with heavier ions (like carbon ions already clinically used), another advantage is the enhanced radiobiological effectiveness due to high linear energy transfer radiation. These particle therapy advantages are unfortunately not thoroughly exploited due to particle range uncertainties. The possibility to monitor the compliance between the ongoing and prescribed dose distribution is a crucial step toward new optimizations in treatment planning and adaptive therapy. The Positron Emission Tomography (PET) is an established quantitative 3D imaging technique for particle treatment verification and, among the isotopes used for PET imaging, the

Indexed as

carbon-11particle acceleratorparticle therapyradioactive ion beamsradioactive isotopestreatment planning

Identifiers

PMID35547661
PMCPMC9081534
OpenAlexW4224323888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.